TRV GP V, LLC

In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), TRV GP V, LLC reported 3 stock positions worth $429.2 million. Its top holding was Rapport Therapeutics (RAPP) at 50.4% of the portfolio, followed by Septerna (SEPN, 40.4%) and Maze Therapeutics (MAZE, 9.2%). Its holdings were unchanged from Q3 2025.

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001990717
Portfolio Value
$429.2M (Q4 2025)
SEC Filing
0001193125-26-051785 ↗ filed Feb 13, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q4 2024: $294.0M Q4 2024 Q1 2025: $125.1M Q1 2025 Q2 2025: $165.7M Q2 2025 Q3 2025: $353.5M Q3 2025 Q4 2025: $429.2M $429.2M Q4 2025 Q1 2026: $401.0M Q1 2026 Q2 2026: $498.2M Q2 2026

Holdings 3 stocks · $429.2M
RAPP Rapport Therapeutics Inc. 50.44% 7,135,233 $216.5M No change
SEPN Septerna Inc. 40.38% 6,215,591 $173.3M No change
MAZE Maze Therapeutics Inc. 9.18% 950,800 $39.4M No change

Portfolio Sells Q3 2025 → Q4 2025
None this quarter.

Portfolio Buys Q3 2025 → Q4 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$498.2MRAPP, SEPN, MAZE
Q1 2026 3$401.0MRAPP, SEPN, MAZE
Q4 2025 3$429.2MRAPP, SEPN, MAZE
Q3 2025 3$353.5MRAPP, SEPN, MAZE
Q2 2025 4$165.7MRAPP, SEPN, MAZE, CRGX
Q1 2025 4$125.1MRAPP, SEPN, MAZE, CRGX
Q4 2024 3$294.0MSEPN, RAPP, CRGX